ATE78699T1 - Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper. - Google Patents
Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper.Info
- Publication number
- ATE78699T1 ATE78699T1 AT82402078T AT82402078T ATE78699T1 AT E78699 T1 ATE78699 T1 AT E78699T1 AT 82402078 T AT82402078 T AT 82402078T AT 82402078 T AT82402078 T AT 82402078T AT E78699 T1 ATE78699 T1 AT E78699T1
- Authority
- AT
- Austria
- Prior art keywords
- chain
- monoclonal antibody
- constituted
- leukemia
- castor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8121836A FR2516794B1 (fr) | 1981-11-20 | 1981-11-20 | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
| EP82402078A EP0080401B1 (de) | 1981-11-20 | 1982-11-15 | Krebshemmende Heilmittel für die Behandlung von T-Leukämien, bestehend aus der A-Kette des Rizinus und einem spezifischen monoklonalen Antikörper |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE78699T1 true ATE78699T1 (de) | 1992-08-15 |
Family
ID=9264235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT82402078T ATE78699T1 (de) | 1981-11-20 | 1982-11-15 | Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US4643895A (de) |
| EP (1) | EP0080401B1 (de) |
| JP (1) | JPS58135821A (de) |
| AT (1) | ATE78699T1 (de) |
| AU (1) | AU561660B2 (de) |
| CA (1) | CA1209472A (de) |
| DE (1) | DE3280408T2 (de) |
| FR (1) | FR2516794B1 (de) |
| NZ (1) | NZ202563A (de) |
| ZA (1) | ZA828048B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2536997B1 (fr) * | 1982-03-11 | 1987-08-07 | Sanofi Sa | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine |
| FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
| US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
| EP0121388B1 (de) * | 1983-03-30 | 1990-06-13 | Lilly Industries Limited | Immunoglobulinkonjugate |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| FR2547731A1 (fr) * | 1983-06-27 | 1984-12-28 | Centre Nat Rech Scient | Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro |
| FR2550944B1 (fr) * | 1983-08-23 | 1985-12-06 | Sanofi Sa | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers |
| JPS60105629A (ja) * | 1983-09-15 | 1985-06-11 | ザ ボ−ド オブ トラステイ−ズ オブ ザ レランド スタンフオ−ド ジユニア ユニバ−シテイ | イムノトキシン |
| FR2564839B1 (fr) * | 1984-05-23 | 1986-11-14 | Sanofi Sa | Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines |
| CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| CA1283661C (en) * | 1984-06-20 | 1991-04-30 | Franz Jansen | Imidazolides, process for their preparation and application as intermediates for the synthesis of cytotoxic conjugates |
| FR2573656B1 (fr) * | 1984-11-29 | 1987-02-27 | Sanofi Sa | Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose |
| FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
| US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US4904481A (en) * | 1985-04-17 | 1990-02-27 | The Board Of Trustess Of Leland Stanford University | Method of conferring immuno-tolerance to a specific antigen |
| ATE87318T1 (de) * | 1985-11-29 | 1993-04-15 | Consolidated Pharmaceuticals L | Ricin-antikoerper-konjugate. |
| EP0252951A4 (de) * | 1986-01-06 | 1988-09-07 | Univ Melbourne | Technetium-antikörper konjugate. |
| US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
| US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
| US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
| US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
| DE68919366T2 (de) * | 1988-09-30 | 1995-05-18 | Neorx Corp | Spaltbare linker zur reduzierung der akkumulierung von immunokonjugaten in nicht-zielorganen. |
| ES2094231T3 (es) * | 1990-07-20 | 1997-01-16 | Pharmacia & Upjohn Ab | Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion. |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
| FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
| EP0044167A3 (de) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Durch einen Antikörper gerichtetes zytotoxisches Mittel |
| FR2521010B1 (fr) * | 1982-02-09 | 1985-07-19 | Sanofi Sa | Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent |
| FR2522968B1 (fr) * | 1982-03-10 | 1986-03-28 | Sanofi Sa | Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine |
| FR2536997B1 (fr) * | 1982-03-11 | 1987-08-07 | Sanofi Sa | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine |
| US4485093A (en) * | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
-
1981
- 1981-11-20 FR FR8121836A patent/FR2516794B1/fr not_active Expired
-
1982
- 1982-11-01 US US06/438,037 patent/US4643895A/en not_active Expired - Fee Related
- 1982-11-03 ZA ZA828048A patent/ZA828048B/xx unknown
- 1982-11-03 CA CA000414789A patent/CA1209472A/en not_active Expired
- 1982-11-10 AU AU90334/82A patent/AU561660B2/en not_active Ceased
- 1982-11-15 AT AT82402078T patent/ATE78699T1/de active
- 1982-11-15 EP EP82402078A patent/EP0080401B1/de not_active Expired - Lifetime
- 1982-11-15 DE DE8282402078T patent/DE3280408T2/de not_active Expired - Fee Related
- 1982-11-19 NZ NZ202563A patent/NZ202563A/en unknown
- 1982-11-20 JP JP57202905A patent/JPS58135821A/ja active Pending
-
1988
- 1988-08-31 US US07/239,071 patent/US4919927A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA828048B (en) | 1983-08-31 |
| NZ202563A (en) | 1986-04-11 |
| CA1209472A (en) | 1986-08-12 |
| FR2516794A1 (fr) | 1983-05-27 |
| JPS58135821A (ja) | 1983-08-12 |
| FR2516794B1 (fr) | 1985-10-25 |
| US4919927A (en) | 1990-04-24 |
| EP0080401A1 (de) | 1983-06-01 |
| AU9033482A (en) | 1983-05-26 |
| AU561660B2 (en) | 1987-05-14 |
| DE3280408D1 (de) | 1992-09-03 |
| DE3280408T2 (de) | 1993-03-04 |
| EP0080401B1 (de) | 1992-07-29 |
| US4643895A (en) | 1987-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3280408D1 (de) | Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper. | |
| IE820815L (en) | Anti-cancer drug. | |
| NL166552B (nl) | Werkwijze voor de bereiding van een fotopolymeriseer- baar materiaal en fotopolymeriseerbaar element verkre- gen onder toepassing van zo'n materiaal. | |
| ATE307585T1 (de) | Substituierte phenylpyrimidine derivate, für die behandlung oder prevention von zns-erkrankungen | |
| DE3869114D1 (de) | Fluessigkristallverbindung und gemische, die diese verbindung enthalten. | |
| IT7823948A0 (it) | Ammidi derivate daltrimetossi-3,4,5-benzene e loro applicazione come prodotti medicinali. | |
| RU92016463A (ru) | Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе | |
| NL175845B (nl) | Uit een pakket van gebogen bladveren samengestelde veer en werkwijze voor het vervaardigen van zo'n samengestelde veer. | |
| DE3882642D1 (de) | Substituierte tetraline, chromane und verwandte verbindungen fuer die behandlung von asthma, arthritis und verwandte krankheiten. | |
| BE853558A (fr) | Nouvelles fluoroacylresorcines substituees et medicaments, cosmetiques et pesticides les renfermant. | |
| NL7605223A (nl) | Werkwijze en inrichting voor de continue extru- sie, evenals gevormde voortbrengselen vervaar- digd onder toepassing van de werkwijze. | |
| NL7807376A (nl) | Werkwijze voor de bereiding van waterrijke, fijndisper- se, bij bewaring houdbare emulsies van siloxanolie. | |
| NL7702090A (nl) | Werkwijze voor de bereiding van gecondenseerde 5,6-gesubstitueerde 4-aminoalkoxy (2) 2,3-pyranon- verbindingen en hun additiezouten en tussenpro- dukten alsmede gevormd farmaceutisch preparaat. | |
| ATE104860T1 (de) | Aktiver wirkstoff und diesen enthaltendes arzneimittel zur verhinderung oder bekaempfung der abstossung von organtransplantaten. | |
| ATE28566T1 (de) | Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin. | |
| FR2521010B1 (fr) | Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent | |
| ATE20519T1 (de) | Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und chloroquin. | |
| NL163512C (nl) | Werkwijze voor de bereiding van 2,3-dihydrobenzofuranyl-5-esters en van bestrijdingsmid- delen die ze bevatten. | |
| NL7505679A (nl) | Werkwijze voor het bereiden van 1,3-bis(halo- methyl)fenobarbital, werkwijze voor het berei- den van anticonvulsieve preparaten met toepas- sing daarvan alsmede zo gevormde farmaceutische preparaten. | |
| NL7705934A (nl) | Werkwijze voor de bereiding van verbenon, myrtenal en pinocarveol uit geoxydeerde terpeenmengsels. | |
| NL7411653A (nl) | Oppervlaktebehandeling voor onderdelen van ijzerlegeringen, die weerstand moeten bieden aan slijtage en zich moeten aanpassen. | |
| NO144416C (no) | Produkt, saerlig lastpall, samt fremgangsmaate til dets fremstilling. | |
| BE835907A (fr) | Procede de deparaffinage d'huiles minerales par traitement avec des solvants, en presence ou l'absence d'uree | |
| EP0039809A3 (de) | Substituierte 2-Amino-5-halogen-benzothiazole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| CH471658A (de) | Form für die Herstellung und zum Verpacken von Bauelementen, z. B. Ornamentsteinen, aus giess- oder schüttbaren Massen |